A picture of a woman with sunglasses on her head smiling in an open field.

For your OAB* patients when an oral pill† fails or
can't be tolerated

NOT TODAY, OAB

BOTOX® provides significant reductions in daily leakage episodes at week 12 (2.5 to 3.0 with BOTOX® vs 0.9 to 1.1 with placebo)1,‡

View clinical Data

Recommend BOTOX® to your appropriate patients, so the day may be theirs, not OAB's.

*OAB = overactive bladder.

†Anticholinergic (AC).

‡Baseline daily leakage episodes: BOTOX® = 5.5; placebo = 5.1 to 5.7.

For your OAB* patients when an oral pill† fails or
can't be tolerated

NOT TODAY, OAB

BOTOX® provides significant reductions in daily leakage episodes at week 12 (2.5 to 3.0 with BOTOX® vs 0.9 to 1.1 with placebo)1,‡

View clinical Data

Recommend BOTOX® to your appropriate patients, so the day may be theirs, not OAB's.

*OAB = overactive bladder.

†Anticholinergic (AC).

‡Baseline daily leakage episodes: BOTOX® = 5.5; placebo = 5.1 to 5.7.

Indication
Adult Bladder Dysfunction

Overactive Bladder
BOTOX® (onabotulinumtoxinA) for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

ACCORDING TO MARKET RESEARCH:

Patients look to you for answers; are you asking the right questions?

According to the 2019 American Urological Association (AUA) Census, 1/3 of healthcare professionals fail to ask OAB patients about their treatment preferences (N = 11,065)2

Circle chart showing 80%

82%

of OAB patients are looking for a specific treatment recommendation from their doctor (N = 119)3,*

*Based on an online survey of OAB patients conducted from 01/2022 to 02/2022.

Use this 4-point scale with patients to categorize the severity of their primary axillary hyperhidrosis.

BOTOX® delivers significant, proven reductions in daily OAB leakage episodes

Mean reductions in daily leakage episodes at week 12 in patients who did not have success with or could not tolerate an anticholinergic (P < 0.001)1

Bar chart showing 45% mean reduction in daily leakage episodes for BOTOX® 100 Units vs 18% for placebo in a clinical study

Mean reductions in daily leakage episodes at week 12 in patients who did not have success with or could not tolerate an anticholinergic (P < 0.001)1

Bar graph showing BOTOX® 100 Units (55% reduction in daily leakage episodes) to placebo (19% reduction) in a clinical study
 

Study 1 and 2 design: Double-blind, placebo-controlled, randomized, multicenter, phase 3, 24-week clinical studies in OAB patients with symptoms of urge urinary incontinence (UUI), urgency, and frequency who had an inadequate response to or intolerable side effects on anticholinergic therapy. Eligible patients had at least 3 UUl episodes and at least 24 micturitions within 3 days. Patients were randomized to BOTOX® 100 Units (n = 557) or placebo (n = 548). Primary endpoint was the mean change from baseline in daily Ul episodes at week 12. ANCOVA model with last-observation-carried-forward (LOCF) imputation was used. Study 1 mean baseline Ul frequency: BOTOX®
100 Units = 5.5/day, placebo = 5.1/day. Study 2 mean baseline UI frequency: BOTOX® 100 Units = 5.5/day, placebo = 5.7/day.1

A doctor in a lab coat with a stethoscope speaking to a patient

BOTOX® safety profile for OAB is well characterized

Most common adverse events were established in pivotal studies1

OAB is treated at its source

BOTOX® is injected directly into the detrusor muscle during an in-office procedure1

Illustration of a medical procedure within a human bladder with close-ups of instruments in action
Next Page